Advancing Laboratory Sustainability: My Green Lab Launches Certification 2.0
Recognized by the United Nations Race to Zero campaign as a key measure for progress toward a zero-carbon future, and recommended by the U.S. EPA, My Green Lab Certification is the world's most trusted green lab certification. The latest updates strengthen the program's impact while enhancing its rigor, integrity, and scalability.
Key features of My Green Lab Certification 2.0 include:
AstraZeneca was the first organization to implement the enhanced program in October 2024, setting the stage for widespread adoption of My Green Lab Certification 2.0. With today's official launch, My Green Lab Certification 2.0 is now ready to deliver measurable environmental and financial outcomes across the scientific community.
'The enhancements to our certification program reflect My Green Lab's commitment to continuous improvement and our dedication to empowering labs to lead the charge in environmental sustainability,' said James Connelly, CEO of My Green Lab. 'With My Green Lab Certification 2.0, we're equipping labs with actionable insights within a user-friendly and powerful platform for driving meaningful change.'
About My Green Lab
My Green Lab® is a nonprofit environmental organization with a mission to build a global culture of sustainability in science. The organization is the world leader in developing internationally recognized sustainability standards for laboratories and laboratory products—bringing sustainability to the community responsible for the world's life-changing medical and technical innovations. Laboratories are some of the most resource-intensive spaces in any industry, but they don't have to be. By introducing a new perspective and proven best practices within a carefully crafted framework, My Green Lab has inspired tens of thousands of scientists and lab professionals to make positive changes in their labs by reducing the environmental impact of their work.
My Green Lab Certification
The world's most trusted green lab certification, guiding scientists and lab teams toward actionable sustainability practices. Supported by third-party verification from Impact Laboratories, My Green Lab Certification has engaged 3,800 labs in 50 countries reaching over 41,000 scientists (as of early 2025).
For media requests, contact Christina Creager at [email protected].
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
2 hours ago
- Business Wire
MedX Health Corp. Names Meghan Geary as Senior Vice President of Operations
MISSISSAUGA, Ontario--(BUSINESS WIRE)--MedX Health Corp. ('MedX' or the 'Company') (TSXV: MDX), the global leader in teledermatology solutions, confirms the appointment of Meghan Geary as the Company's Senior Vice President of Operations, effective immediately. With over 10 years experience in building scalable programs across SaaS and high-growth healthcare companies, Geary will oversee strategic operations, drive organization performance, and support MedX's continued growth trajectory. "I'm excited to join MedX at such a pivotal stage of its journey," said Geary. "Throughout my career, I've focused on scaling programs that streamline processes and promote cross-functional alignment. I look forward to collaborating with the MedX team to optimize operations and ensure the Company is positioned for long-term success." The Company's CEO, John Gevisser added: 'Meghan brings formidable experience to MedX at a time when we are scaling operations across different markets. Having previously worked closely with her, I understand what a vital asset to our team she is. Her ability to lead strategic programs, adjust and direct processes and improve organizational performance will play a central role in our next phase of growth. Meghan critically understands that our deep and dynamic image store is central to our AI and SaaS strategy.' About MedX Health Corp. MedX Health Corp., headquartered in Ontario, Canada, is a leader in non-invasive skin assessment and teledermatology. Its proprietary SIAscopy ® technology, integrated into the DermSecure ® platform, enables pain-free, accurate imaging of skin lesions for rapid dermatologist review. These products are cleared for use in 38 countries including by Health Canada, the U.S. Food and Drug Administration ('FDA'), the Therapeutic Goods Administration and Conformité Européenne, for use in Canada, the U.S., Australia, New Zealand, the United Kingdom, the European Union and Turkey. MedX's advanced telemedicine platform enables healthcare professionals to quickly and accurately assess suspicious moles, lesions, and other skin conditions through its proprietary imaging technology, SIAscopy ®, and its secure, cloud-based patient management system, DermSecure ®. SIAscopy® is the only technology capable of capturing five high-resolution images, including four spectrophotometric scans that penetrate 2mm below the skin's surface. Visit: https// This Media Release may contain forward-looking statements, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties.
Business Wire
7 hours ago
- Business Wire
Sonendo Strengthens Leadership Team With Promotion of John McGaugh to Chief Operating Officer
LAGUNA HILLS, Calif.--(BUSINESS WIRE)--Sonendo, Inc. ('Sonendo' or the 'Company') (OTC Pink: SONX), a leading dental technology company and developer of the GentleWave® System, today announced the promotion of John McGaugh to Chief Operating Officer. Mr. McGaugh previously held the position of Senior Vice President of Operations. 'Since Sonendo embarked on its strategic reset in early-2024, the Company has stabilized revenue, generated significant leverage in gross margin, and meaningfully lowered total operating expenses, adjusted EBITDA loss and cash burn,' stated Bjarne Bergheim, President and Chief Executive Officer of Sonendo. 'John has been a significant contributor to all those improvements, and we expect he will continue to drive additional operating leverage as the Company continues to execute its plans to achieve profitability. John is a valuable member of the team, and I am excited to see him take on the role of Chief Operating Officer.' In addition to his previous responsibilities overseeing quality, manufacturing, supply chain, and technical services operations, Mr. McGaugh now has oversight of Sonendo's capital and consumables sales teams and commercial operations. Mr. McGaugh has over 20 years overseeing global manufacturing operations. He joined Sonendo in May 2023 and has been instrumental in leading significant operational efficiencies with console assembly and procedure instrument margin contributions. Prior to his time at Sonendo, Mr. McGaugh served as a multi-site operational leader for Abbott Vascular. In addition to his experience at Abbott, Mr. McGaugh has held leadership roles at Boston Scientific and American Medical Systems. About Sonendo Sonendo is a commercial-stage medical technology Company focused on saving teeth from tooth decay, the most prevalent chronic disease globally. Sonendo develops and manufactures the GentleWave® System, an innovative technology platform designed to treat tooth decay by cleaning and disinfecting the microscopic spaces within teeth without the need to remove tooth structure. The system utilizes a proprietary mechanism of action, which combines procedure fluid optimization, broad-spectrum acoustic energy and advanced fluid dynamics, to debride and disinfect deep regions of the complex root canal system in a less invasive procedure that preserves tooth structure. The clinical benefits of the GentleWave System when compared to conventional methods of root canal therapy include improved clinical outcomes, such as superior cleaning that is independent of root canal complexity and tooth anatomy, high and rapid rates of healing and minimal to no post-operative pain. In addition, the GentleWave System can improve the workflow and economics of dental practices. For more information about Sonendo and the GentleWave System, please visit To find a GentleWave doctor in your area, please visit Forward Looking Statements This news release includes forward-looking statements (statements which are not historical facts) within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, the Company's ability to continue to drive additional operating leverage and/or execute its plans to achieve profitability, whether as a result of Mr. McGaugh or otherwise. You are cautioned that such statements are not guarantees of future performance and that our actual results may differ materially from those set forth in the forward-looking statements. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions; speak only as of the date they are made; and, as a result, are subject to risks and uncertainties that may change at any time. Factors that could cause the Company's actual results to differ materially from these forward-looking statements are described in detail in the 'Risk Factors' section of the Company's Annual Report on Form 10-K that was filed with the Securities and Exchange Commission on March 26, 2025. Such filings are available at The Company undertakes no obligation to publicly update or revise forward-looking statements to reflect subsequent developments, events, or circumstances, except as may be required under applicable securities laws. Readers are cautioned not to put undue reliance on forward-looking statements, and the Company assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise.
Boston Globe
7 hours ago
- Boston Globe
‘Natural' sex drugs are a spreading health risk in West Africa
Products like Attoté, a manufactured beverage, and other so-called artisanal sex stimulants made in the Ivory Coast contain high levels of sildenafil, the drug commonly known as Viagra, according to public health officials and laboratory tests obtained by The New York Times. The pills are manufactured in India, smuggled into the Ivory Coast, crushed, mixed with other ingredients, and sold for $1.50 domestically, $15 in France, and $20 in the US. Advertisement Up to half of the drugs in West Africa are unregulated, according to the United Nations' drug agency. More than 500,000 people are estimated to die every year in sub-Saharan Africa from the consumption of dangerous, unregulated medications. Sexual stimulants like Attoté are among the most frequently reported, according to the World Health Organization. Advertisement 'It's coming in from everywhere,' Dr. Assane Coulibaly, the head of the Ivory Coast's pharmaceutical regulatory authority, said about the sexual stimulants. 'It's a war.' Though there is no public data available on the consumption of sexual stimulants in the Ivory Coast, public health officials have warned of the growing risks. Emergency doctors have reported seeing prolonged erections that can lead to necrosis, and patients with frequent migraines and drooling. 'Sexual omnipotence is glorified,' said Dr. Mamadou Kamagaté, a professor of pharmacology. 'Popular beliefs have taken over scientific reasoning, and people ignore the side effects.' One afternoon last fall on an empty lot in Korhogo, a city in northern Ivory Coast, a steady stream of men riding in shiny SUVs or on cheap motorbikes drove past street vendors seated on wobbly plastic chairs. The men were looking for Attoté, a pink, bitter drink purported to improve male performance. The production of Attoté had been suspended a few months earlier by the government, citing misleading advertising and health risks, including death. But the demand remained high. On the empty lot, the main production plant for the drug was at a standstill, but shelves in the plant's adjacent store were still stocked with Attoté bottles. 'I last so much longer,' said Bruno Siloué, a high school student looking to purchase Attoté. 'That's what I take when I have a tough game ahead of me,' said Tenena Soro, 29, a construction worker, referring to a date. Few of the men circling the lot seemed worried about the side effects, which include migraines, stomach pains, uncontrolled drooling, and worrying heartbeats, according to more than two dozen health officials interviewed for this article. Advertisement 'Every man taking this complains about strong migraines. In the news, we hear about men suffering from heart attacks,' said Dr. Fadley Coulibaly, an Ivorian doctor who has raised awareness about the dangers of consuming such drugs. 'And yet, there's no awareness.' In a back alley in downtown Korhogo, herbal scents wafted in the air one afternoon. Consumers milled about buying various supplements and unregulated drugs meant to treat everything from stomach pain to erectile dysfunction. Herbal medicine remains highly popular across West Africa, and some entrepreneurs like Djakalia Ouattara, Attoté's founder, have found success in the market. In an interview with a Times journalist, Ouattara claimed that his product was made only with plants sourced from local markets and nearby villages. But the recipe remains secret, he added. Attoté's concentration of sildenafil is eight times higher than the recommended dose, according to the Ivorian Agency for Pharmaceutical Regulation, which provided the laboratory tests obtained by the Times. Last year, police seized more than 40 tons of sildenafil pills smuggled from India and stored in disused warehouses in Korhogo. 'Even if we use sildenafil, if it cures people, why is it bad?' said Moussa Soro, one of Ouattara's sons. Soro, 29, claimed that Attoté helps with various ailments and even infertility, and said that he began working with his father to produce the product at age 8. Neither of the men holds a degree in medicine. Ouattara, a burly man who wears a fedora and is known across the Ivory Coast as 'Dr. Attoté,' was once a mechanic. When his business was run into the ground, he had a revelation, said two of his sisters, Natou and Mariam Ouattara, both Attoté resellers. Advertisement Djakalia Ouattara supposedly inherited the sacred recipe for Attoté from his deceased grandfather, and believes it is his divine responsibility to share its powers with other men. Representatives for the company declined to provide official sales figures. But Soro said that production started at 5 a.m. and ended at 1 a.m. and that the Attoté plant produced thousands of bottles every day. Key markets for the company include Senegal and Ghana in West Africa, as well as France, Belgium, and the US. Production discreetly resumed shortly after the government ban last year, according to Ouattara. It's the same recipe but under the new name Fêrêlaha, which roughly translates to 'Take the shame off me.' In his living room in Korhogo, Ouattara showed a membership card for the Ivory Coast's National Program for the Promotion of Traditional Medicine, an agency overseen by the country's Health Ministry. The card was issued after the ban, he said. This article originally appeared in
